Benjamin Edwards Inc. Has $1.32 Million Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Benjamin Edwards Inc. lifted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 18,454.8% during the third quarter, Holdings Channel.com reports. The firm owned 58,262 shares of the company’s stock after purchasing an additional 57,948 shares during the period. Benjamin Edwards Inc.’s holdings in 10x Genomics were worth $1,315,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. FMR LLC lifted its position in 10x Genomics by 2.7% in the 3rd quarter. FMR LLC now owns 13,367,979 shares of the company’s stock valued at $301,849,000 after acquiring an additional 357,470 shares in the last quarter. ARK Investment Management LLC lifted its holdings in shares of 10x Genomics by 15.4% in the third quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock valued at $242,743,000 after purchasing an additional 1,436,582 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of 10x Genomics by 3.7% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company’s stock valued at $143,907,000 after buying an additional 230,145 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in 10x Genomics by 69.6% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,143,067 shares of the company’s stock worth $119,483,000 after buying an additional 2,521,289 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C purchased a new stake in 10x Genomics in the 2nd quarter valued at $11,612,000. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Price Performance

Shares of TXG stock opened at $15.23 on Friday. 10x Genomics, Inc. has a 1 year low of $12.95 and a 1 year high of $57.90. The company’s fifty day simple moving average is $16.53 and its two-hundred day simple moving average is $19.35. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -9.95 and a beta of 1.84.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. The business had revenue of $151.65 million for the quarter, compared to analysts’ expectations of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.51) EPS. Equities research analysts anticipate that 10x Genomics, Inc. will post -1.4 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Stephens reiterated an “overweight” rating and issued a $30.00 target price on shares of 10x Genomics in a research note on Thursday, October 10th. The Goldman Sachs Group decreased their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research note on Wednesday, October 30th. Leerink Partners initiated coverage on 10x Genomics in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $35.00 target price on the stock. Citigroup dropped their price target on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. Finally, Canaccord Genuity Group reduced their price objective on 10x Genomics from $32.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, October 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.19.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.